FARMINGDALE, N.Y., Nov. 23, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery, wound and burn care, and other surgical specialties, unveiled a newly redesigned SonicOne O.R. device and hand piece at the Southern Regional Burn Conference in Dallas, Texas. The new SonicOne O.R. was enthusiastically received by the surgeons and burn teams in attendance from all across the United States.
Misonix also held its first ever National Distributor Training program just prior to the start of the conference. More than 16 distributors representing the SonicOne O.R. product line throughout the United States attended a workshop to learn about the unique clinical advantages associated with the use of the SonicOne O.R. for ultrasonic wound debridement. The clinical portion of the training was conducted by William Hickerson, MD, Professor, Plastic Surgery, University of Tennessee Health Science Center, Memphis; Chief of Burn Surgery, College of Medicine.
"The key to any successful medical device is the commitment to training both the people who represent the product as well as the physicians who use it. Misonix has demonstrated its commitment to excellence through the type of training program just completed for the SonicOne O.R.," said Dr. Hickerson regarding the National Distributor Training Program.
"The SonicOne O.R. system is an innovative ultrasonic surgical debridement system that allows surgeons to address the challenges that chronic wounds present to them, the patient, and the healthcare system. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process. Events such as this week's training for our sales team are going to be a key component to our success in the marketplace," stated Scott Ludecker, Senior Vice President, Global Sales and Marketing with Misonix.
"We are very encouraged to see that SonicOne O.R. is playing such an important part in the treatment and recovery of burn patients. We are committed to innovating further in this market to enhance the clinical utility of SonicOne O.R. in the coming year," said Michael A. McManus Jr., President and Chief Executive Officer of Misonix.
About Misonix Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.